Objective:To investigate the therapeutic effect of Zhenju hypotensive tablet combined with nifedipine sustained-release tablet in the treatment of essential hypertension, and its influence on the vascular endothelial function, expression of cystatin C (CysC), homocysteine (Hcy) and hypersensitive C-reactive protein (hs-CRP).Methods:From September 2018 to September 2019, 182 patients with essential hypertension were enrolled in Zhuji Hospital of Traditional Chinese Medicine.They were divided into observation group (91 cases) and control group (91 cases) according to the random digital table method.The control group was given nifedipine sustained-release tablets, while the observation group received Zhenju hypotensive tablets on the basis of the control group.The course of treatment in both two groups was 12 weeks.After treatment, the changes of blood pressure, endothelial function, CysC, Hcy and hs-CRP levels and adverse reactions were compared.Results:The total effective rate of the observation group (91.21%) was higher than that of the control group (79.12%) (χ 2=5.262, P<0.05). The SBP and DBP in the two groups were decreased after treatment for 12 weeks ( tobservation group=29.054, 26.702, tcontrol grou P=27.449, 20.145, all P<0.05). The SBP and DBP in the observation group were lower than those in the control group ( t=12.704, 8.177, all P<0.05). After treatment for 12 weeks, the plasma level of ET-1 in the two groups were lower than those before treatment, and the level of NO the two groups were higher than those before treatment ( tobservation group=27.388, 18.644, tcontrol group=9.480, 9.657, all P<0.05). The plasma level of ET-1 in the observation group was lower than that in the control group, and the level of NO in the observation group was higher than that in the control group, the differences were statistically significant( t=22.384, 9.134, all P<0.05). The levels of CysC, Hcy and hs-CRP in the two groups after treatment for 12 weeks were lower than those before treatment ( tobservation group=31.586, 23.159, 29.776, tcontrol grou P=11.641, 13.649, 16.521, all P<0.05). The levels of CysC, Hcy and hs-CRP in the observation group were lower than those in the control group ( t=17.193, 10.554, 14.671, all P<0.05). The adverse reaction in the observation group was less than those in the control group (χ 2=7.959, P<0.05). Conclusion:Zhenju hypotensive tablet combined with nifedipine sustained-release tablet has good therapeutic effect in the treatment of essential hypertension.It can improve the vascular endothelial function, reduce the expression of CysC, Hcy and hs-CRP, and has fewer adverse reactions.

Objective To evaluate the safety of national immunization program (NIP) vaccines and non-NIP vaccines in Fujian Province from 2011 to 2015.Methods The adverse events following immunization (AEFI) case information reported in Fujian Province from 2011 to 2015 was collected from the National AEFI Information Management System and vaccination data of NIP vaccines (11 species) and nonNIP vaccines (19 species) in the same period in Fujian Province were collected from the National Immunization Program Information Management System.The collected monitoring data were descriptively analyzed.The total and severe AEFI reporting rates and their 95％ confidence intervals (CI) were calculated.Results From 2011 to 2015,a total of 70 976 300 doses of vaccines were inoculated in Fujian Province and a total of 8 987 cases of AEFI were reported,including 192 cases (2.14％) of severe AEFI.The incidence (95％CI) of reported AEFI was 12.66 (12.40-12.93) per 100 000 doses and the incidence (95％CI) of reported severe AEFI was 2.71 (2.34-3.12) per one million doses.A total of 55 702 100 doses of NIP vaccines were inoculated and 7 347 cases of AEFI were reported,of which 138 (1.88％) were severe AEFI cases.The incidence (95％ CI) of reported AEFI was 13.19 (12.89-1.49)per 100 000 doses of NIP vaccines and the incidence (95％ CI) of reported severe AEFI was 2.48 (2.08-2.93) per one million doses.Among the 11 NIP vaccines,the incidence (95％ CI) of reported AEFI ranged from 0.95 (0.88-1.13) per 100 000 doses to 43.71 (40.72-46.75) per 100 000 doses and the incidence (95％ CI) of reported severe AEFI ranged from 1.04 (0.32-1.76) per one million doses to 6.41 (2.78-10.04) per one million doses.A total of 15 271 600 doses of non-NIP vaccines were inoculated and 1 640 cases of AEFI were reported,of which 54 (3.54％) were severe AEFI cases.The total incidence (95％ CI) of reported AEFI was 10.74 (10.23-11.27) per 100 000 doses and the incidence (95％ CI) of reported severe AEFI was 3.54 (2.66-4.61) per one million doses.Among the 19 non-NIP vaccines,the incidence (95 ％ CI) of reported AEFI ranged from 2.06 (0.38-3.71) per 100 000 doses to 45.22 (35.29-55.10)per 100 000 doses and the incidence (95％ CI) of reported severe AEFI ranged from 0.52 (0-1.53) per one million doses to 20.89 (0-44.51) per one million doses.Conclusion From 2011 to 2015,the incidences of reported AEFI and severe AEFI for NIP and non-NIP vaccines circulated in Fujian Province were low,which had good safety.

Objective To evaluate the safety of national immunization program (NIP) vaccines and non-NIP vaccines in Fujian Province from 2011 to 2015.Methods The adverse events following immunization (AEFI) case information reported in Fujian Province from 2011 to 2015 was collected from the National AEFI Information Management System and vaccination data of NIP vaccines (11 species) and nonNIP vaccines (19 species) in the same period in Fujian Province were collected from the National Immunization Program Information Management System.The collected monitoring data were descriptively analyzed.The total and severe AEFI reporting rates and their 95％ confidence intervals (CI) were calculated.Results From 2011 to 2015,a total of 70 976 300 doses of vaccines were inoculated in Fujian Province and a total of 8 987 cases of AEFI were reported,including 192 cases (2.14％) of severe AEFI.The incidence (95％CI) of reported AEFI was 12.66 (12.40-12.93) per 100 000 doses and the incidence (95％CI) of reported severe AEFI was 2.71 (2.34-3.12) per one million doses.A total of 55 702 100 doses of NIP vaccines were inoculated and 7 347 cases of AEFI were reported,of which 138 (1.88％) were severe AEFI cases.The incidence (95％ CI) of reported AEFI was 13.19 (12.89-1.49)per 100 000 doses of NIP vaccines and the incidence (95％ CI) of reported severe AEFI was 2.48 (2.08-2.93) per one million doses.Among the 11 NIP vaccines,the incidence (95％ CI) of reported AEFI ranged from 0.95 (0.88-1.13) per 100 000 doses to 43.71 (40.72-46.75) per 100 000 doses and the incidence (95％ CI) of reported severe AEFI ranged from 1.04 (0.32-1.76) per one million doses to 6.41 (2.78-10.04) per one million doses.A total of 15 271 600 doses of non-NIP vaccines were inoculated and 1 640 cases of AEFI were reported,of which 54 (3.54％) were severe AEFI cases.The total incidence (95％ CI) of reported AEFI was 10.74 (10.23-11.27) per 100 000 doses and the incidence (95％ CI) of reported severe AEFI was 3.54 (2.66-4.61) per one million doses.Among the 19 non-NIP vaccines,the incidence (95 ％ CI) of reported AEFI ranged from 2.06 (0.38-3.71) per 100 000 doses to 45.22 (35.29-55.10)per 100 000 doses and the incidence (95％ CI) of reported severe AEFI ranged from 0.52 (0-1.53) per one million doses to 20.89 (0-44.51) per one million doses.Conclusion From 2011 to 2015,the incidences of reported AEFI and severe AEFI for NIP and non-NIP vaccines circulated in Fujian Province were low,which had good safety.

OBJECTIVETo investigate the application of medpor and split-thickness skin graft in formation of cranioauricular sulcus during auricular reconstruction with Nagata method.

METHODSThe first stage operation was fulfilled according to the Nagata two-stage method which involves fabrication and grafting of the costal cartilage framework. The second-stage ear elevation operation was undertaken 6 months later to form the cranioauricular sulcus. Split-thickness skin was taken from temporal and accipital area. After releasing the auricular framework and transplanting C shaped medpor at the rear side of framework, the temporaparietal fascia flap was transferred to cover postauricular medpor and framework. Then the split-thickness skin graft was implant on the fascia surface.

RESULTSFrom July 2010 to August 2012, 20 cases (22 ears) were treated. Partial necrosis of temporaparietal fascia flap and framework exposure happened in 1 case. Successful ear reconstruction was achieved in other cases with satisfactory cranioauricular sulcus during the follow-up period of 6-18 months (average, 13 months).

CONCLUSIONSThe application of medpor and split-thickness skin graft in the ear elevation of Nagata method for auricular reconstruction for microtia can achieve satisfactory results. It not only avoids the obvious scar in the donor site due to harvesting full-thickness and intermediate-thickness skin, but also reduces chest trauma due to harvesting costal cartilage.

Costal Cartilage ; transplantation ; Dermatologic Surgical Procedures ; methods ; Ear Auricle ; surgery ; Fascia ; Humans ; Polyethylenes ; therapeutic use ; Skin Transplantation ; Surgical Flaps ; transplantation

OBJECTIVE To investigate the optimal surgical approach and compatible material for large nasal septal perforation.METHODS Operations were underwent via labiogingival groove approach under endoscope.Double layer of flaps were perichondrium of nasal septal cartilage,base of nasal cavity and inferior nasal meatus on the left and acellular dermal matrix (ADM) on the right and the two flaps were adhered with ear-cerebral glue (EC).RESULTS All of 36 cases were successfully repaired and no reperforation occurred after following-up for 3 months to 2 years.CONCLUSION Large mucosal flaps with wide pedicel and abundant blood supply and ADM of good biocompatibility provide a higher survival rate of the flaps.This method has the advantages of wide field of vision,less damage of the donated area and short time of operation.It is an optimal and practical method for repair of the large nasal septal perforation.

Objective To evaluate the effect of traditional Chinese herbal medicine on the prevention of hemolytic disease caused by maternal-fetal blood group incompatibility.Methods A total of 126 Chinese patients with maternal-fetal blood group incompatibility were studied, including 105 cases of ABO type and 21 cases of Rh type incompatibility. The traditional Chinese herbal medicine was used for preventative treatment in 79 cases, and 47 cases served as controls. The prescription consisted of Herba leonuri 500 g, white peony root 180 g, Banksia rose 12 g, root of Chinese angelica 150 g and Rhizomal ligustica 150 g.Results Preventative treatment with traditional Chinese herbal medicine significantly reduced the perinatal mortality rate in cases of Rh type incompatibility, from 50.0% in the control group to 7.7% in the treatment group (P<0.05). There was no death in the cases of ABO incompatibility. The traditional Chinese herbal medicine also decreased the degree of hemolysis. The percentage of severe cases in the control group was 29.8%, while it was 15.2% in the treatment group (P=0.05). The duration of treatment was closely related to the outcomes. In patients who used traditional Chinese herbal medicine for more than 10 weeks, the incidence of severe hemolysis was 8.2%, compared with 38.9% in those treated for less than 10 weeks (P<0.05). The change of serum immune antibody (A and /or B) titers during the treatment was a very important predictive factor for the outcome of the pregnancy.Conclusion Traditional Chinese herbal medicine is effective not only for ABO type but also for Rh type maternal-fetal blood group incompatibility, with no side effects.